| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
69,020,000 |
| Market
Cap: |
106.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6003 - $4.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NGM Biopharmaceuticals is a biopharmaceutical company. Co. has five product candidates in the clinic, three wholly-owned by Co. (NGM707, NGM120 and aldafermin), one being progressed by its collaborator, Merck Sharp & Dohme Corp., or Merck (MK-3655) and one optionable by Merck (NGM621). Co.'s oncology product candidates include NGM707, NGM831, NGM438 and NGM120 and their related compounds. NGM621 was engineered to bind to, and be a long-acting inhibitor of, complement C3 with the treatment goal of reducing disease progression in patients with geographic atrophy, secondary to age-related macular degeneration. MK-3655 isin Phase 2b development for the treatment of nonalcoholic steatohepatitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
94,704 |
94,704 |
9,606,382 |
| Total Buy Value |
$0 |
$64,854 |
$64,854 |
$87,820,003 |
| Total People Bought |
0 |
4 |
4 |
5 |
| Total Buy Transactions |
0 |
10 |
10 |
130 |
| Total Shares Sold |
0 |
0 |
0 |
85,082 |
| Total Sell Value |
$0 |
$0 |
$0 |
$438,308 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-10-11 |
4 |
AS |
$20.41 |
$306,150 |
D/D |
(15,000) |
914,449 |
|
-27% |
|
| Lieu Hsiao |
SVP, Chief Medical Officer |
• – – |
2021-10-05 |
4 |
AS |
$22.00 |
$44,000 |
D/D |
(2,000) |
0 |
|
-26% |
|
| Lieu Hsiao |
SVP, Chief Medical Officer |
• – – |
2021-10-05 |
4 |
OE |
$12.06 |
$24,120 |
D/D |
2,000 |
2,000 |
|
- |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-09-14 |
4 |
AS |
$25.54 |
$384,892 |
D/D |
(15,000) |
929,449 |
|
-43% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-09-13 |
4 |
AS |
$25.59 |
$390,414 |
D/D |
(15,000) |
944,449 |
|
-44% |
|
| Lieu Hsiao |
SVP, Chief Medical Officer |
• – – |
2021-08-12 |
4 |
S |
$23.50 |
$188,000 |
D/D |
(8,000) |
0 |
|
20% |
|
| Lieu Hsiao |
SVP, Chief Medical Officer |
• – – |
2021-08-12 |
4 |
OE |
$12.06 |
$96,480 |
D/D |
8,000 |
8,000 |
|
- |
|
| Lieu Hsiao |
SVP, Chief Medical Officer |
• – – |
2021-08-11 |
4 |
S |
$23.00 |
$51,934 |
D/D |
(2,258) |
0 |
|
19% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-08-10 |
4 |
AS |
$23.15 |
$347,250 |
D/D |
(15,000) |
959,449 |
|
-20% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-08-09 |
4 |
AS |
$23.81 |
$366,972 |
D/D |
(15,000) |
974,449 |
|
-26% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-06-03 |
4 |
OE |
$1.44 |
$99,999 |
D/D |
69,444 |
989,449 |
|
- |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-05-03 |
4 |
AS |
$27.62 |
$690,500 |
D/D |
(25,000) |
920,005 |
|
-16% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-04-12 |
4 |
AS |
$24.65 |
$616,250 |
D/D |
(25,000) |
945,005 |
|
-15% |
|
| Pierce Valerie L |
SVP, GC & CCOOfficer |
• – – |
2021-03-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,610 |
|
-23% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-03-01 |
4 |
AS |
$26.66 |
$666,500 |
D/D |
(25,000) |
970,005 |
|
-19% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-02-16 |
4 |
AS |
$28.75 |
$718,750 |
D/D |
(25,000) |
995,005 |
|
-26% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-01-05 |
4 |
OE |
$0.60 |
$90,000 |
D/D |
150,000 |
1,020,005 |
|
- |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2021-01-04 |
4 |
AS |
$29.27 |
$732,116 |
D/D |
(25,000) |
870,005 |
|
-4% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-12-14 |
4 |
AS |
$27.59 |
$700,276 |
D/D |
(25,000) |
895,005 |
|
1% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-11-02 |
4 |
AS |
$17.70 |
$442,500 |
D/D |
(25,000) |
920,005 |
|
68% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-10-12 |
4 |
AS |
$17.02 |
$425,500 |
D/D |
(25,000) |
945,005 |
|
64% |
|
| Goeddel David V |
Managing Partner |
– • • |
2020-09-02 |
4 |
B |
$17.67 |
$487,604 |
D/D |
27,595 |
1,827,025 |
3.92 |
48% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-09-02 |
4 |
B |
$17.67 |
$487,604 |
D/D |
27,595 |
1,827,025 |
2.45 |
48% |
|
| Goeddel David V |
Managing Partner |
– • • |
2020-09-01 |
4 |
B |
$17.64 |
$643,754 |
D/D |
36,494 |
1,799,430 |
3.92 |
49% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-09-01 |
4 |
B |
$17.64 |
$643,754 |
D/D |
36,494 |
1,799,430 |
2.45 |
49% |
|
107 Records found
|
|
Page 3 of 5 |
|
|
